beta blocker: be contraindicated in diabetes mellitus

from Quasimodo
0.2 0.4 0.6 0.8 Plausible Typical Remarkable Salient

Related concepts

Parents agent
Weight: 0.65
, high blood pressure
Weight: 0.63
, heart disease
Weight: 0.63
, vasodilator
Weight: 0.62
Siblings atenolol
Weight: 0.53
, lung cancer
Weight: 0.33
, cystic fibrosis
Weight: 0.33
, agonist
Weight: 0.32
, blood clot
Weight: 0.32

Related properties

Property Similarity
be contraindicated in diabetes mellitus 1.00
be contraindicated in diabetes 0.99
be contraindicated in disease 0.95
be contraindicated in asthma 0.94
be contraindicated with asthma 0.94
be contraindicated in myasthenia gravis 0.94
be contraindicated in patients with asthma 0.93
be contraindicated in pheochromocytoma 0.93
be contraindicated in pregnancy 0.93
be contraindicated in copd 0.93

Priors about this statement

Cues

0.2 0.4 0.6 0.8 Joint Necessity Sufficiency Implication Entailment Contradiction Entropy

Evidence

0.2 0.4 0.6 0.8 Plausible Typical Remarkable Salient

Clauses

Remarkability exclusitivity between siblings

0.09
Rule weight: 0.13
Evidence weight: 0.72
Similarity weight: 0.93
Evidence: 0.68
¬ Remarkable(beta blocker, be contraindicated in diabetes mellitus) ⋁
Evidence: 0.42
¬ Remarkable(atenolol, be contraindicated in pregnancy)
0.07
Rule weight: 0.13
Evidence weight: 0.56
Similarity weight: 0.94
Evidence: 0.68
¬ Remarkable(beta blocker, be contraindicated in diabetes mellitus) ⋁
Evidence: 0.65
¬ Remarkable(atenolol, be contraindicated in asthma)

Remarkability from sibling implausibility

0.53
Rule weight: 0.60
Evidence weight: 0.94
Similarity weight: 0.94
Evidence: 0.78
Plausible(beta blocker, be contraindicated in diabetes mellitus) ⋁
Evidence: 0.65
Remarkable(atenolol, be contraindicated in asthma) ⋁
Evidence: 0.75
¬ Plausible(atenolol, be contraindicated in asthma)
0.51
Rule weight: 0.60
Evidence weight: 0.91
Similarity weight: 0.93
Evidence: 0.78
Plausible(beta blocker, be contraindicated in diabetes mellitus) ⋁
Evidence: 0.42
Remarkable(atenolol, be contraindicated in pregnancy) ⋁
Evidence: 0.70
¬ Plausible(atenolol, be contraindicated in pregnancy)

Salient implies Plausible

0.23
Rule weight: 0.28
Evidence weight: 0.81
Similarity weight: 1.00
Evidence: 0.78
Plausible(beta blocker, be contraindicated in diabetes mellitus) ⋁
Evidence: 0.87
¬ Salient(beta blocker, be contraindicated in diabetes mellitus)

Similarity expansion

0.75
Rule weight: 0.85
Evidence weight: 0.89
Similarity weight: 0.99
Evidence: 0.87
Salient(beta blocker, be contraindicated in diabetes mellitus) ⋁
Evidence: 0.85
¬ Salient(beta blocker, be contraindicated in diabetes)
0.74
Rule weight: 0.85
Evidence weight: 0.93
Similarity weight: 0.94
Evidence: 0.81
Typical(beta blocker, be contraindicated in diabetes mellitus) ⋁
Evidence: 0.40
¬ Typical(beta blocker, be contraindicated in myasthenia gravis)
0.72
Rule weight: 0.85
Evidence weight: 0.91
Similarity weight: 0.94
Evidence: 0.87
Salient(beta blocker, be contraindicated in diabetes mellitus) ⋁
Evidence: 0.72
¬ Salient(beta blocker, be contraindicated in myasthenia gravis)
0.72
Rule weight: 0.85
Evidence weight: 0.92
Similarity weight: 0.93
Evidence: 0.87
Salient(beta blocker, be contraindicated in diabetes mellitus) ⋁
Evidence: 0.66
¬ Salient(beta blocker, be contraindicated in copd)
0.72
Rule weight: 0.85
Evidence weight: 0.85
Similarity weight: 0.99
Evidence: 0.81
Typical(beta blocker, be contraindicated in diabetes mellitus) ⋁
Evidence: 0.80
¬ Typical(beta blocker, be contraindicated in diabetes)
0.72
Rule weight: 0.85
Evidence weight: 0.90
Similarity weight: 0.94
Evidence: 0.87
Salient(beta blocker, be contraindicated in diabetes mellitus) ⋁
Evidence: 0.79
¬ Salient(beta blocker, be contraindicated with asthma)
0.72
Rule weight: 0.85
Evidence weight: 0.91
Similarity weight: 0.93
Evidence: 0.81
Typical(beta blocker, be contraindicated in diabetes mellitus) ⋁
Evidence: 0.50
¬ Typical(beta blocker, be contraindicated in copd)
0.72
Rule weight: 0.85
Evidence weight: 0.89
Similarity weight: 0.94
Evidence: 0.87
Salient(beta blocker, be contraindicated in diabetes mellitus) ⋁
Evidence: 0.84
¬ Salient(beta blocker, be contraindicated in asthma)
0.71
Rule weight: 0.85
Evidence weight: 0.90
Similarity weight: 0.93
Evidence: 0.87
Salient(beta blocker, be contraindicated in diabetes mellitus) ⋁
Evidence: 0.78
¬ Salient(beta blocker, be contraindicated in pregnancy)
0.71
Rule weight: 0.85
Evidence weight: 0.89
Similarity weight: 0.94
Evidence: 0.78
Plausible(beta blocker, be contraindicated in diabetes mellitus) ⋁
Evidence: 0.51
¬ Plausible(beta blocker, be contraindicated in myasthenia gravis)
0.71
Rule weight: 0.85
Evidence weight: 0.89
Similarity weight: 0.93
Evidence: 0.87
Salient(beta blocker, be contraindicated in diabetes mellitus) ⋁
Evidence: 0.84
¬ Salient(beta blocker, be contraindicated in pheochromocytoma)
0.71
Rule weight: 0.85
Evidence weight: 0.89
Similarity weight: 0.93
Evidence: 0.87
Salient(beta blocker, be contraindicated in diabetes mellitus) ⋁
Evidence: 0.87
¬ Salient(beta blocker, be contraindicated in patients with asthma)
0.71
Rule weight: 0.85
Evidence weight: 0.83
Similarity weight: 0.99
Evidence: 0.78
Plausible(beta blocker, be contraindicated in diabetes mellitus) ⋁
Evidence: 0.76
¬ Plausible(beta blocker, be contraindicated in diabetes)
0.70
Rule weight: 0.85
Evidence weight: 0.87
Similarity weight: 0.94
Evidence: 0.81
Typical(beta blocker, be contraindicated in diabetes mellitus) ⋁
Evidence: 0.67
¬ Typical(beta blocker, be contraindicated in asthma)
0.70
Rule weight: 0.85
Evidence weight: 0.89
Similarity weight: 0.93
Evidence: 0.78
Plausible(beta blocker, be contraindicated in diabetes mellitus) ⋁
Evidence: 0.53
¬ Plausible(beta blocker, be contraindicated in copd)
0.69
Rule weight: 0.85
Evidence weight: 0.87
Similarity weight: 0.94
Evidence: 0.81
Typical(beta blocker, be contraindicated in diabetes mellitus) ⋁
Evidence: 0.72
¬ Typical(beta blocker, be contraindicated with asthma)
0.68
Rule weight: 0.85
Evidence weight: 0.86
Similarity weight: 0.93
Evidence: 0.81
Typical(beta blocker, be contraindicated in diabetes mellitus) ⋁
Evidence: 0.74
¬ Typical(beta blocker, be contraindicated in pregnancy)
0.68
Rule weight: 0.85
Evidence weight: 0.85
Similarity weight: 0.94
Evidence: 0.78
Plausible(beta blocker, be contraindicated in diabetes mellitus) ⋁
Evidence: 0.69
¬ Plausible(beta blocker, be contraindicated in asthma)
0.68
Rule weight: 0.85
Evidence weight: 0.85
Similarity weight: 0.94
Evidence: 0.78
Plausible(beta blocker, be contraindicated in diabetes mellitus) ⋁
Evidence: 0.69
¬ Plausible(beta blocker, be contraindicated with asthma)
0.67
Rule weight: 0.85
Evidence weight: 0.85
Similarity weight: 0.93
Evidence: 0.81
Typical(beta blocker, be contraindicated in diabetes mellitus) ⋁
Evidence: 0.82
¬ Typical(beta blocker, be contraindicated in patients with asthma)
0.67
Rule weight: 0.85
Evidence weight: 0.85
Similarity weight: 0.93
Evidence: 0.78
Plausible(beta blocker, be contraindicated in diabetes mellitus) ⋁
Evidence: 0.70
¬ Plausible(beta blocker, be contraindicated in pregnancy)
0.67
Rule weight: 0.85
Evidence weight: 0.84
Similarity weight: 0.93
Evidence: 0.81
Typical(beta blocker, be contraindicated in diabetes mellitus) ⋁
Evidence: 0.85
¬ Typical(beta blocker, be contraindicated in pheochromocytoma)
0.67
Rule weight: 0.85
Evidence weight: 0.79
Similarity weight: 0.99
Evidence: 0.68
Remarkable(beta blocker, be contraindicated in diabetes mellitus) ⋁
Evidence: 0.66
¬ Remarkable(beta blocker, be contraindicated in diabetes)
0.66
Rule weight: 0.85
Evidence weight: 0.83
Similarity weight: 0.93
Evidence: 0.78
Plausible(beta blocker, be contraindicated in diabetes mellitus) ⋁
Evidence: 0.78
¬ Plausible(beta blocker, be contraindicated in patients with asthma)
0.66
Rule weight: 0.85
Evidence weight: 0.83
Similarity weight: 0.93
Evidence: 0.78
Plausible(beta blocker, be contraindicated in diabetes mellitus) ⋁
Evidence: 0.79
¬ Plausible(beta blocker, be contraindicated in pheochromocytoma)
0.65
Rule weight: 0.85
Evidence weight: 0.81
Similarity weight: 0.93
Evidence: 0.68
Remarkable(beta blocker, be contraindicated in diabetes mellitus) ⋁
Evidence: 0.58
¬ Remarkable(beta blocker, be contraindicated in pheochromocytoma)
0.63
Rule weight: 0.85
Evidence weight: 0.80
Similarity weight: 0.93
Evidence: 0.68
Remarkable(beta blocker, be contraindicated in diabetes mellitus) ⋁
Evidence: 0.63
¬ Remarkable(beta blocker, be contraindicated in pregnancy)
0.63
Rule weight: 0.85
Evidence weight: 0.78
Similarity weight: 0.94
Evidence: 0.68
Remarkable(beta blocker, be contraindicated in diabetes mellitus) ⋁
Evidence: 0.68
¬ Remarkable(beta blocker, be contraindicated with asthma)
0.62
Rule weight: 0.85
Evidence weight: 0.78
Similarity weight: 0.93
Evidence: 0.68
Remarkable(beta blocker, be contraindicated in diabetes mellitus) ⋁
Evidence: 0.67
¬ Remarkable(beta blocker, be contraindicated in patients with asthma)
0.60
Rule weight: 0.85
Evidence weight: 0.75
Similarity weight: 0.94
Evidence: 0.68
Remarkable(beta blocker, be contraindicated in diabetes mellitus) ⋁
Evidence: 0.77
¬ Remarkable(beta blocker, be contraindicated in asthma)
0.60
Rule weight: 0.85
Evidence weight: 0.76
Similarity weight: 0.93
Evidence: 0.68
Remarkable(beta blocker, be contraindicated in diabetes mellitus) ⋁
Evidence: 0.74
¬ Remarkable(beta blocker, be contraindicated in copd)
0.58
Rule weight: 0.85
Evidence weight: 0.72
Similarity weight: 0.94
Evidence: 0.68
Remarkable(beta blocker, be contraindicated in diabetes mellitus) ⋁
Evidence: 0.86
¬ Remarkable(beta blocker, be contraindicated in myasthenia gravis)

Typical and Remarkable implies Salient

0.13
Rule weight: 0.14
Evidence weight: 0.93
Similarity weight: 1.00
Evidence: 0.87
Salient(beta blocker, be contraindicated in diabetes mellitus) ⋁
Evidence: 0.81
¬ Typical(beta blocker, be contraindicated in diabetes mellitus) ⋁
Evidence: 0.68
¬ Remarkable(beta blocker, be contraindicated in diabetes mellitus)

Typical implies Plausible

0.39
Rule weight: 0.48
Evidence weight: 0.82
Similarity weight: 1.00
Evidence: 0.78
Plausible(beta blocker, be contraindicated in diabetes mellitus) ⋁
Evidence: 0.81
¬ Typical(beta blocker, be contraindicated in diabetes mellitus)

Typicality and Rermarkability incompatibility between siblings

0.06
Rule weight: 0.14
Evidence weight: 0.47
Similarity weight: 0.94
Evidence: 0.68
¬ Remarkable(beta blocker, be contraindicated in diabetes mellitus) ⋁
Evidence: 0.79
¬ Typical(atenolol, be contraindicated in asthma)
0.06
Rule weight: 0.14
Evidence weight: 0.44
Similarity weight: 0.93
Evidence: 0.68
¬ Remarkable(beta blocker, be contraindicated in diabetes mellitus) ⋁
Evidence: 0.82
¬ Typical(atenolol, be contraindicated in pregnancy)